AU2002259309B2 - Antineoplastic combinations - Google Patents

Antineoplastic combinations Download PDF

Info

Publication number
AU2002259309B2
AU2002259309B2 AU2002259309A AU2002259309A AU2002259309B2 AU 2002259309 B2 AU2002259309 B2 AU 2002259309B2 AU 2002259309 A AU2002259309 A AU 2002259309A AU 2002259309 A AU2002259309 A AU 2002259309A AU 2002259309 B2 AU2002259309 B2 AU 2002259309B2
Authority
AU
Australia
Prior art keywords
mtor inhibitor
cci
alkylating agent
rapamycin
antineoplastic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002259309A
Other languages
English (en)
Other versions
AU2002259309A1 (en
Inventor
Gary Dukart
James Joseph Gibbons Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of AU2002259309A1 publication Critical patent/AU2002259309A1/en
Application granted granted Critical
Publication of AU2002259309B2 publication Critical patent/AU2002259309B2/en
Priority to AU2008202690A priority Critical patent/AU2008202690A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002259309A 2001-06-01 2002-05-29 Antineoplastic combinations Ceased AU2002259309B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2008202690A AU2008202690A1 (en) 2001-06-01 2008-06-18 Antineoplastic combination

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29523601P 2001-06-01 2001-06-01
US29519001P 2001-06-01 2001-06-01
US60/295,236 2001-06-01
US60/295,190 2001-06-01
PCT/US2002/016737 WO2002098416A2 (en) 2001-06-01 2002-05-29 Antineoplastic combinations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2008202690A Division AU2008202690A1 (en) 2001-06-01 2008-06-18 Antineoplastic combination

Publications (2)

Publication Number Publication Date
AU2002259309A1 AU2002259309A1 (en) 2003-05-08
AU2002259309B2 true AU2002259309B2 (en) 2008-05-01

Family

ID=26968972

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2002259309A Ceased AU2002259309B2 (en) 2001-06-01 2002-05-29 Antineoplastic combinations
AU2008202690A Abandoned AU2008202690A1 (en) 2001-06-01 2008-06-18 Antineoplastic combination

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2008202690A Abandoned AU2008202690A1 (en) 2001-06-01 2008-06-18 Antineoplastic combination

Country Status (17)

Country Link
EP (1) EP1392286A2 (enExample)
JP (1) JP2004532883A (enExample)
KR (1) KR100875611B1 (enExample)
CN (1) CN100496485C (enExample)
AU (2) AU2002259309B2 (enExample)
BR (1) BR0210101A (enExample)
CA (1) CA2447732A1 (enExample)
CO (1) CO5540294A2 (enExample)
EA (1) EA007530B1 (enExample)
HU (1) HUP0400006A2 (enExample)
IL (1) IL158800A0 (enExample)
MX (1) MXPA03010907A (enExample)
NO (1) NO20035317L (enExample)
NZ (1) NZ529877A (enExample)
PL (1) PL367267A1 (enExample)
SG (1) SG153647A1 (enExample)
WO (1) WO2002098416A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2762140T (lt) * 2001-02-19 2017-06-26 Novartis Ag Solidinių smegenų navikų gydymas rapamicino dariniu
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
AR046194A1 (es) 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
CN108421044A (zh) 2005-02-03 2018-08-21 综合医院公司 治疗吉非替尼耐药性癌症的方法
BRPI0618042A2 (pt) * 2005-11-04 2011-08-16 Wyeth Corp usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica
EP2275103B1 (en) 2005-11-21 2014-04-23 Novartis AG mTOR inhibitors in the treatment of endocrine tumors
GB0523658D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
US20090023768A1 (en) * 2006-02-24 2009-01-22 Novartis Ag Rapamycin derivatives for treating neuroblastoma
JP2009532503A (ja) * 2006-04-05 2009-09-10 ノバルティス アクチエンゲゼルシャフト 癌を処置するための治療剤の組合せ
LT2481402T (lt) * 2007-03-07 2018-10-25 Abraxis Bioscience, Llc Nanodalelė, apimanti rapamiciną ir albuminą, kaip priešvėžinį agentą
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN102641270A (zh) 2008-06-17 2012-08-22 惠氏有限责任公司 含有hki-272和长春瑞滨的抗肿瘤组合
US8669273B2 (en) 2008-08-04 2014-03-11 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
IL264349B2 (en) 2009-04-06 2024-01-01 Wyeth Llc Regimen comprising neratinib for the treatment of cancer
CN103721189A (zh) * 2013-12-27 2014-04-16 刘玉含 一种脑膜瘤护理药物及其制备方法
CN105168204A (zh) * 2015-09-06 2015-12-23 江志鑫 一种含有丝裂霉素的抗结肠癌药物组合物
CN119732959A (zh) * 2024-12-31 2025-04-01 吉林大学 具有mTOR抑制能力的制剂在制备抗肿瘤联合用药物组合物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
SG43072A1 (en) * 1991-06-18 1997-10-17 American Home Prod Method of treating adult t-cell leukemia/lymphoma
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
LT2762140T (lt) * 2001-02-19 2017-06-26 Novartis Ag Solidinių smegenų navikų gydymas rapamicino dariniu

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Geoerger B et al. Antitumor activity of the rapamycin analogue CCl-199 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Research 2001, Vol 4, No 61, pages 1527-1532. *
Shi Y et al. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Research, 1995 Vol 55, No 9, pages 1982-1988. *

Also Published As

Publication number Publication date
AU2008202690A1 (en) 2008-07-10
CO5540294A2 (es) 2005-07-29
NZ529877A (en) 2006-08-31
EA007530B1 (ru) 2006-10-27
NO20035317L (no) 2003-12-22
BR0210101A (pt) 2004-06-08
WO2002098416A2 (en) 2002-12-12
EP1392286A2 (en) 2004-03-03
EA200301319A1 (ru) 2004-04-29
CN1646120A (zh) 2005-07-27
SG153647A1 (en) 2009-07-29
KR20040025923A (ko) 2004-03-26
JP2004532883A (ja) 2004-10-28
PL367267A1 (en) 2005-02-21
KR100875611B1 (ko) 2008-12-24
NO20035317D0 (no) 2003-11-28
MXPA03010907A (es) 2004-02-17
CA2447732A1 (en) 2002-12-12
IL158800A0 (en) 2004-05-12
WO2002098416A3 (en) 2003-03-13
HUP0400006A2 (hu) 2004-04-28
CN100496485C (zh) 2009-06-10

Similar Documents

Publication Publication Date Title
US20030008923A1 (en) Antineoplastic combinations
AU2008202690A1 (en) Antineoplastic combination
EP1385551B1 (en) Antineoplastic combinations comprising cci-779 (rapamycin derivative) together with gemcitabine or fluorouracil
RU2451524C2 (ru) Противоопухолевые комбинации с ингибиторами mtor, герцептином и/или hki-272
US7189735B2 (en) Use of CCI-779 as an antineoplastic agent
US20020183239A1 (en) Antineoplastic combinations
US20070105887A1 (en) Antineoplastic combinations of temsirolimus and sunitinib malate
ZA200309816B (en) Antineoplastic combinations
AU2002259309A1 (en) Antineoplastic combinations
US20050187184A1 (en) Antineoplastic combinations
AU2016259316B2 (en) Antineoplastic combinations with mTOR inhibitor, herceptin, and/or HKI-272
AU2002227313B2 (en) Use of CCI-779 as an antineoplastic agent
AU2013204788B2 (en) Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
AU2002257123A1 (en) Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
HK1060062B (en) Antineoplastic combinations comprising cci-779 (rapamycin derivative) together with gemcitabine or fluorouracil
HK40009377A (en) Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
AU2002227313A1 (en) Use of CCI-779 as an antineoplastic agent

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired